Literature DB >> 17932702

Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity.

S A Sadiq, C A Poopatana.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17932702     DOI： 10.1007/s00415-007-0566-z

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

Review 1.  Evidence-based review of the literature on intrathecal delivery of pain medication.

Authors:  G Bennett; M Serafini; K Burchiel; E Buchser; A Classen; T Deer; S Du Pen; F M Ferrante; S J Hassenbusch; L Lou; J Maeyaert; R Penn; R K Portenoy; R Rauck; K D Willis; T Yaksh
Journal:  J Pain Symptom Manage       Date:  2000-08       Impact factor: 3.612

2.  Chronic intrathecal morphine for intractable pain.

Authors:  R D Penn; J A Paice
Journal:  J Neurosurg       Date:  1987-08       Impact factor: 5.115

3.  Leg edema from intrathecal opiate infusions.

Authors:  J A Aldrete
Journal:  Eur J Pain       Date:  2000       Impact factor: 3.931

4.  Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain.

Authors:  S Gatscher; R Becker; E Uhle; H Bertalanffy
Journal:  Acta Neurochir Suppl       Date:  2002

5.  [Implantable continuous epidural morphine infusion system for relief of chronic cancer pain].

Authors:  K Moritake; H Handa; S Umeda; T Nishioka; H Suwa; T Konishi; M Takaya
Journal:  No Shinkei Geka       Date:  1986-05

Review 6.  Intrathecal baclofen in pain management.

Authors:  Marc Slonimski; Stephen E Abram; Robert E Zuniga
Journal:  Reg Anesth Pain Med       Date:  2004 May-Jun       Impact factor: 6.288
  6 in total
  10 in total

1.  Use of intrathecal clonidine in patients with multiple sclerosis or spastic paraparesis.

Authors:  Joseph K Ho; Saud A Sadiq
Journal:  J Neurol       Date:  2011-11-05       Impact factor: 4.849

2.  The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.

Authors:  Jenny L Wilkerson; Jasmine S Felix; Luis F Restrepo; Mohd Imran Ansari; Andrew Coop; Lance R McMahon
Journal:  J Pharmacol Exp Ther       Date:  2019-06-24       Impact factor: 4.030

Review 3.  Multiple sclerosis-related central pain disorders.

Authors:  Turo J Nurmikko; Sameer Gupta; Kate Maclver
Journal:  Curr Pain Headache Rep       Date:  2010-06

Review 4.  Pharmacological management of pain in patients with multiple sclerosis.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Drugs       Date:  2010-07-09       Impact factor: 9.546

Review 5.  Management of pain in multiple sclerosis: a pharmacological approach.

Authors:  Claudio Solaro; Michele Messmer Uccelli
Journal:  Nat Rev Neurol       Date:  2011-08-16       Impact factor: 42.937

Review 6.  Intrathecal Baclofen Monotherapy and Polyanalgesia for Treating Chronic Pain in Patients with Severe Spasticity.

Authors:  Anuj Marathe; Sameer Allahabadi; Alaa Abd-Elsayed; Michael Saulino; Jonathan M Hagedorn; Vwaire Orhurhu; Jay Karri
Journal:  Curr Pain Headache Rep       Date:  2021-12-11

7.  The discriminative stimulus effects of baclofen and gamma hydroxybutyrate in C57BL/6J mice.

Authors:  Jenny L Wilkerson; Takato Hiranita; Wouter Koek; Lance R McMahon
Journal:  Behav Pharmacol       Date:  2022-08-03       Impact factor: 2.277

Review 8.  Pain and multiple sclerosis: pathophysiology and treatment.

Authors:  Claudio Solaro; Erika Trabucco; Michele Messmer Uccelli
Journal:  Curr Neurol Neurosci Rep       Date:  2013-01       Impact factor: 5.081

Review 9.  Neuropathic Pain in Multiple Sclerosis and Its Animal Models: Focus on Mechanisms, Knowledge Gaps and Future Directions.

Authors:  Ersilia Mirabelli; Stella Elkabes
Journal:  Front Neurol       Date:  2021-12-16       Impact factor: 4.003

Review 10.  Multiple sclerosis-induced neuropathic pain: pharmacological management and pathophysiological insights from rodent EAE models.

Authors:  Nemat Khan; Maree T Smith
Journal:  Inflammopharmacology       Date:  2014-02       Impact factor: 4.473
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.